3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
3
Sarcoma
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
2
Melanoma
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Docetaxel
3
trastuzumab deruxtecan
1
tanespimycin
1
sargramostim
1
pertuzumab
1
pembrolizumab
1
larotrectinib
1
entrectinib
1
entinostat
1
alectinib
1
aldesleukin
1
Vorinostat
1
Trastuzumab
1
Thalidomide
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Indinavir
1
Immunotherapy
1
Immunohistochemistry
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Gemcitabine
1
Flow Cytometry
1
Filgrastim
1
Fentanyl
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
trastuzumab deruxtecan
×
Dermatologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled